Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The macrophage surface and phagocytic machinery refers to the integrated system of receptors and signaling pathways that mediate the recognition and engulfment of target particles, such as pathogens and apoptotic cells (PMID: 29083588). This machinery is governed by a balance of "eat me" signals, like calreticulin, and "don't eat me" signals, most notably the CD47-SIRPα axis (PMID: 22119904). In many cancers, tumor cells overexpress CD47 to evade macrophage-mediated destruction, effectively "cloaking" themselves from the immune system. Therapeutic strategies targeting this machinery, such as Magrolimab, aim to block these inhibitory interactions to restore the phagocytic capacity of macrophages against malignant cells (PMID: 30612867). Beyond oncology, the phagocytic machinery is essential for tissue remodeling and the resolution of inflammation by clearing cellular debris and preventing the release of pro-inflammatory intracellular contents (PMID: 31043704).
Modulation of pro-phagocytic (eat-me) and anti-phagocytic (don't-eat-me) signaling pathways to enhance the clearance of target cells or pathogens (PMID: 30612867).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Macrophage surface and phagocytic machinery.